PATENT CLAIM ANALYSIS

Application Number: 16050102
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "004800"]

Abstract:
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Claim (Index 18):
An amylin analogue according to  claim 17  wherein M is a lipophilic substituent comprising a hydrocarbon chain having from 10 to 24 C atoms.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.4898
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15698743', '14398260', '11278014', '14800627', '15442229']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7682076000301382
- 35 USC 102 Novelty (BERT): 0.7415232581139907
- Combined Prediction Score: 0.7655391658385234
- Mean Citation Score: 487.11570200000006
- Max Citation Score: 847.1067
- Similarity Product: 822.2629158130824

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test